title: Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease.
abstract: OBJECTIVE
  Aim of the study was to evaluate the response to hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease (IBD).
  
  
  METHODS
  A total of 47 patients with IBD (25 ulcerative colitis, 14 Crohn's disease, and 8 indeterminate colitis) ages 3 to 17 years were compared with 50 healthy age- and sex-matched controls. Screening for hepatitis A and B serology was carried out before vaccination. Susceptible cases received 20 mg of recombinant DNA vaccine for hepatitis B (0, 1, and 6 months)and 720 milliELISA units of inactivated hepatitis A virus vaccine (HAV) (0 and 6 months). Postvaccination serologic evaluation was performed 1 month after the last dose of primary vaccination, 1 month after the booster dose, and once every year during follow-up.
  
  
  RESULTS
  A total of 23 patients and 35 controls received HAV and protective anti-HAV antibodies were developed in all of the patients and controls (P =1.00). Forty-seven patients and 50 controls received hepatitis B vaccine and 70.2% of the patients versus 90% of the controls achieved seroprotection(anti-HBs titers 10 mIU/mL) 1 month after primary vaccination (95% confidence interval 0.71–0.87, P = 0.02). The overall seroprotection rates were 96% in controls and 85.1% in patients after the whole hepatitis B vaccination series (95% confidence interval 0.83–0.95, P = 0.08). No significant reduction was observed in antibody response among patients and controls during the follow-up period.
  
  
  CONCLUSIONS
  The rate of seroconversion to the hepatitis B vaccine was lower in pediatric patients with IBD than in healthy controls and hepatitis A vaccine was highly immunogenic among patients with IBD.
authors.affiliation: Division of Pediatric Gastroenterology, Sisli Etfal Training and Research Hospital, Istanbul, Turkey.
authors.forename: Nafiye
authors.initials: N
authors.lastname: Urganci
authors.forename: Derya
authors.initials: D
authors.lastname: Kalyoncu
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003093:Colitis, Ulcerative / Q000097:blood / Q000276:immunology; D003424:Crohn Disease / Q000097:blood / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D035922:Hepatitis A Antibodies / Q000032:analysis; D022362:Hepatitis A Vaccines / Q000276:immunology*; D017957:Hepatitis A Virus, Human / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D056724:Immunity, Humoral; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000276:immunology*; D008297:Male; D011446:Prospective Studies; D019444:Vaccines, DNA / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA; D015164:Vaccines, Inactivated
keywords: childhood, Crohn's Disease, hepatitis A vaccine, hepatitis B vaccine, inflammatory bowel disease, ulcerative colitis